Status:
COMPLETED
Nebulized Dexmedetomidine Versus Oral Sumatriptan in Treatment of Post Dural Puncture Headache in Cesarean Section
Lead Sponsor:
Fayoum University Hospital
Conditions:
Post-Dural Puncture Headache
Eligibility:
FEMALE
18-40 years
Phase:
NA
Brief Summary
comparison between oral sumatriptan and Nebulized Dexmedetomidine in Post Dural Puncture Headache in Cesarean Section
Detailed Description
A total of 48 patients will be randomly chosen to receive either inhaled dexmedetomidine (Group D, n= 24) or oral sumatriptan (Group S, n= 24) by a random sequence number generated by the computer kep...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Pregnant female aged between 18 and 40 years old.
- ASA II and III undergoing elective caesarean section.
- Diagnosed with Postdural puncture headache with visual analogue score (VAS) ≥ 4 and Lybecker classification score ≥ 2.
- Exclusion criteria:
- Patient refusal.
- History of primary headaches such as migraine, cluster and tension headaches.
- Hypersensitivity of dexmedetomidine or sumatriptan.
- Hypertensive disorders of the pregnancy.
- Contraindication to spinal anesthesia as coagulopathy or infection at site of injection.
- Symptoms of ischemic heart disease (IHD) e.g. angina.
- Cerebrovascular disease e.g. stroke or transient ischemic attacks (TIAs).
- Using of Monoamine oxidase inhibitors (MAOIs) in the last 24h.
Exclusion
Key Trial Info
Start Date :
November 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06514040
Start Date
November 27 2023
End Date
September 30 2024
Last Update
March 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fayoum University hospital
El Fayoum Qesm, Faiyum Governorate, Egypt